Axsome Therapeutics, Inc.
0HKF.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.66B
Close$
Share Statistics
| Market cap | $8.66 Billion |
|---|---|
| Enterprise Value | $8.56 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.68 |
| Beta | 0.76 |
| Outstanding Shares | 51,799,708 |
Return
| Return on Equity | -230.05% |
|---|---|
| Return on Assets | -25.17% |
| Return on Invested Capital | -57.44% |
Valuation & Multiples
| P/E Ratio | -44.89 |
|---|---|
| PEG | -644.62 |
| Price to Sales | 11.2 |
| Price to Book Ratio | 156.8 |
| Enterprise Value to Revenue | 11.03 |
| Enterprise Value to EBIT | -49.53 |
| Enterprise Value to Net Income | -45 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 2.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$221.11 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
$254.32 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Axsome Therapeutics Inc
712 employees
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...